

Brian D Lehmann

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7375769/brian-d-lehmann-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

9,294
citations

34
h-index

67
g-index

67
ext. papers

10,925
ext. citations

7.2
avg, IF

5.91
L-index

#	Paper	IF	Citations
61	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. <i>Journal of Clinical Investigation</i> , 2011 , 121, 2750-67	15.9	3125
60	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007 , 1773, 1263-84	4.9	1532
59	Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. <i>PLoS ONE</i> , 2016 , 11, e0157368	3.7	590
58	Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. <i>Clinical Cancer Research</i> , 2013 , 19, 5533-40	12.9	476
57	Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. <i>Cancer Discovery</i> , 2014 , 4, 232-45	24.4	310
56	Senescence-associated exosome release from human prostate cancer cells. <i>Cancer Research</i> , 2008 , 68, 7864-71	10.1	310
55	Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. <i>Journal of Pathology</i> , 2014 , 232, 142-50	9.4	267
54	Subtyping of triple-negative breast cancer: implications for therapy. <i>Cancer</i> , 2015 , 121, 8-16	6.4	212
53	New strategies for triple-negative breast cancer--deciphering the heterogeneity. <i>Clinical Cancer Research</i> , 2014 , 20, 782-90	12.9	210
52	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. <i>Breast Cancer Research</i> , 2014 , 16, 406	8.3	199
51	TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. <i>Cancer Informatics</i> , 2012 , 11, 147-56	2.4	161
50	Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. <i>Oncogene</i> , 2008 , 27, 4086-95	9.2	128
49	BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. <i>Clinical Cancer Research</i> , 2013 , 19, 6696-702	12.9	122
48	Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 2723-33	12.9	119
47	Triple-negative breast cancer: molecular subtypes and new targets for therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , e31-9	7.1	83
46	Targeting prostate cancer based on signal transduction and cell cycle pathways. <i>Cell Cycle</i> , 2008 , 7, 1745-62	4.7	80
45	A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. <i>Cell Cycle</i> , 2007 , 6, 595-605	4.7	80

44	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. <i>Clinical Cancer Research</i> , 2017 , 23, 4035-4045	12.9	79
43	Clinical implications of molecular heterogeneity in triple negative breast cancer. <i>Breast</i> , 2015 , 24 Suppl 2, S36-40	3.6	76
42	Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. <i>Cancer Research</i> , 2014 , 74, 3180-94	10.1	76
41	A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. <i>PLoS ONE</i> , 2015 , 10, e0125482	3.7	76
40	p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. <i>Cell Cycle</i> , 2012 , 11, 4579-88	4.7	73
39	Patient-derived breast tumor xenografts facilitating personalized cancer therapy. <i>Breast Cancer Research</i> , 2013 , 15, 201	8.3	69
38	Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. <i>Advances in Enzyme Regulation</i> , 2007 , 47, 64-103		63
37	Multi-perspective quality control of Illumina exome sequencing data using QC3. <i>Genomics</i> , 2014 , 103, 323-8	4.3	61
36	Targeting mutant p53 in human tumors. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3648-50	2.2	59
35	RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. <i>Breast Cancer Research</i> , 2010 , 12, R41	8.3	58
34	The Utilization of Formalin Fixed-Paraffin-Embedded Specimens in High Throughput Genomic Studies. <i>International Journal of Genomics</i> , 2017 , 2017, 1926304	2.5	44
33	Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. <i>BMC Cancer</i> , 2016 , 16, 143	4.8	42
32	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2111-2123	12.9	41
31	Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. <i>Oncotarget</i> , 2011 , 2, 610-26	3.3	38
30	Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. <i>Breast Cancer Research</i> , 2014 , 16, R69	8.3	37
29	Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. <i>BioMed Research International</i> , 2013 , 2013, 915636	3	36
28	Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 298, H1088-95	5.2	34
27	Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. <i>Oncotarget</i> , 2015 , 6, 21353-68	3.3	31

26	Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. <i>Cancer Research</i> , 2016 , 76, 4850-60	10.1	28
25	RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library. <i>BioMed Research International</i> , 2015 , 2015, 862130	3	26
24	Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data. <i>Briefings in Bioinformatics</i> , 2016 , 17, 224-32	13.4	23
23	SPARCL1 suppresses metastasis in prostate cancer. <i>Molecular Oncology</i> , 2013 , 7, 1019-30	7.9	23
22	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	22
21	Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. <i>BMC Cancer</i> , 2017 , 17, 241	4.8	20
20	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. <i>Advances in Enzyme Regulation</i> , 2008 , 48, 113-35		20
19	Distinct roles for p107 and p130 in Rb-independent cellular senescence. <i>Cell Cycle</i> , 2008 , 7, 1262-8	4.7	15
18	The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. <i>Genes</i> , 2018 , 9,	4.2	14
17	RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining. <i>International Journal of Genomics</i> , 2016 , 2016, 9837310	2.5	14
16	Estimating relative mitochondrial DNA copy number using high throughput sequencing data. <i>Genomics</i> , 2017 , 109, 457-462	4.3	13
15	Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. <i>Cancer Biology and Therapy</i> , 2007 , 6, 1165-70	4.6	12
14	Detection of internal exon deletion with exon Del. <i>BMC Bioinformatics</i> , 2014 , 15, 332	3.6	10
13	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. <i>Nature Communications</i> , 2021 , 12, 6276	17.4	10
12	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. <i>Molecular Cancer Research</i> , 2019 , 17, 1842-1853	6.6	7
11	Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1005-1005	2.2	5
10	Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility. <i>Oncotarget</i> , 2019 , 10, 133-151	3.3	5
9	Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. <i>PLoS ONE</i> , 2020 , 15, e0231711	3.7	5

8	Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. <i>Nature Communications</i> , 2021 , 12, 5184	17.4	5
7	A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. <i>PLoS ONE</i> , 2013 , 8, e54979	3.7	4
6	Practicality of identifying mitochondria variants from exome and RNAseq data. <i>BMC Bioinformatics</i> , 2015 , 16, P6	3.6	3
5	LR Hunting: A Random Forest Based Cell-Cell Interaction Discovery Method for Single-Cell Gene Expression Data. <i>Frontiers in Genetics</i> , 2021 , 12, 708835	4.5	1
4	Tissue-specific expression of p73 and p63 isoforms in human tissues. <i>Cell Death and Disease</i> , 2021 , 12, 745	9.8	0
3	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy 2008 , 81-114		
2	Abstract PD3-04: Multi-omics characterization of triple-negative breast cancer identifies therapeutic vulnerabilities and epigenetic immune suppression in the mesenchymal subtype. <i>Cancer Research</i> , 2022 , 82, PD3-04-PD3-04	10.1	
1	Abstract P5-09-01: Using isogenic model systems to determine mechanisms regulating mutant p53 protein stability in breast cancer cells. <i>Cancer Research</i> , 2022 , 82, P5-09-01-P5-09-01	10.1	